These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32053745)

  • 1. Quality of phase I clinical drug trials: Influence of organizational management factors.
    Zhao Y; Yang Q; Zhang X
    J Clin Pharm Ther; 2020 Oct; 45(5):968-975. PubMed ID: 32053745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality Management Model for Phase I Clinical Drug Trials: A Structural Equation Model.
    Zhao Y; Yang QX; Wang D; Zhang XP
    Curr Med Sci; 2020 Jun; 40(3):586-593. PubMed ID: 32681264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment.
    Leach MW; Clarke DO; Dudal S; Han C; Li C; Yang Z; Brennan FR; Bailey WJ; Chen Y; Deslandes A; Loberg LI; Mayawala K; Rogge MC; Todd M; Chemuturi NV
    Clin Pharmacol Ther; 2021 Jun; 109(6):1395-1415. PubMed ID: 32757299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality assessment of phase I dose-finding cancer trials: proposal of a checklist.
    Zohar S; Lian Q; Levy V; Cheung K; Ivanova A; Chevret S
    Clin Trials; 2008; 5(5):478-85. PubMed ID: 18827040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and influencing factors of compliance behaviors of investigators in clinical trials.
    Shen YH; Li MZ; Zhang XP; Li ZQ; Wang LJ
    J Huazhong Univ Sci Technolog Med Sci; 2014 Apr; 34(2):284-288. PubMed ID: 24710946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The i3+3 design for phase I clinical trials.
    Liu M; Wang SJ; Ji Y
    J Biopharm Stat; 2020 Mar; 30(2):294-304. PubMed ID: 31304864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microdosing Studies in Children: A US Regulatory Perspective.
    Roth-Cline M; Nelson RM
    Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration-controlled trials. What does the future hold?
    Johnston A; Holt DW
    Clin Pharmacokinet; 1995 Feb; 28(2):93-9. PubMed ID: 7736691
    [No Abstract]   [Full Text] [Related]  

  • 10. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical risk management in early phase clinical trials.
    Coates S; Täubel J; Lorch U
    Eur J Clin Pharmacol; 2019 Apr; 75(4):483-496. PubMed ID: 30569285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations.
    Dombernowsky T; Haedersdal M; Lassen U; Thomsen SF
    Trials; 2019 Dec; 20(1):708. PubMed ID: 31829234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scientific white paper on concentration-QTc modeling.
    Garnett C; Bonate PL; Dang Q; Ferber G; Huang D; Liu J; Mehrotra D; Riley S; Sager P; Tornoe C; Wang Y
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):383-397. PubMed ID: 29209907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial?
    Rissmann R; Szabadi E
    Br J Clin Pharmacol; 2019 Jul; 85(7):1389-1390. PubMed ID: 31020696
    [No Abstract]   [Full Text] [Related]  

  • 15. [Relatively good safety in Swedish phase I trials. A survey of studies reported to the Medical Products Agency during 3 years].
    Glazer A; Hedenmalm K
    Lakartidningen; 2008 Sep 10-16; 105(37):2482-4. PubMed ID: 19006863
    [No Abstract]   [Full Text] [Related]  

  • 16. Strategic inclusion of regions in multiregional clinical trials.
    Song SY; Chee D; Kim E
    Clin Trials; 2019 Feb; 16(1):98-105. PubMed ID: 30444138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated titration designs for phase I clinical trials in oncology.
    Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
    J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration.
    Zhang Y; Wang Y; Khurana M; Sachs HC; Zhu H; Burckart GJ; Alexander J; Yao LP; Wang J
    Clin Pharmacol Ther; 2020 Jul; 108(1):90-98. PubMed ID: 32030741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.